sulmazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3574 | 73384-60-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.62 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.41 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.80 hours | Lombardo F, Berellini G, Obach RS |
| Vd (Volume of distribution) | 1.67 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 20.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.48 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.20 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 1.25 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:38147 | cardiotonic drugs |
| CHEBI has role | CHEBI:50218 | phosphodiesterase inhibitors |
| CHEBI has role | CHEBI:63957 | adenosine A1 receptor antagonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.72 | acidic |
| pKa2 | 4.6 | Basic |
| pKa3 | 1.29 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 4.68 | CHEMBL | |||||
| Phosphodiesterase 3 | Enzyme | IC50 | 4.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 86315-52-8 | SECONDARY_CAS_RN |
| C0075619 | UMLSCUI |
| CHEBI:34988 | CHEBI |
| CHEMBL286020 | ChEMBL_ID |
| CHEMBL2110680 | ChEMBL_ID |
| C029758 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5353 | PUBCHEM_CID |
| 4925 | INN_ID |
| HK56EH9K44 | UNII |
| 5839 | INN_ID |
Pharmaceutical products:
None